Clinical evidence with amlodipine The long-acting third-generation dihydropyridine calcium antagonist amlodipine is one of the most commonly used antihypertensive agents, and is approved for the treatment of HTN and angina at doses from 2. Comparisons of amlodipine and valsartan Although not the focus of this review, some comparisons of amlodipine and valsartan are relevant to the discussion of the combination of both drugs.
Economic evidence In HTN without any other associated cardiovascular risk factor, the treatment cost increases as the target for HTN is lowered but this effect is attenuated when the population tested is older or has higher cardiovascular risk. Clinical value As reviewed, this combination is effective in terms of reduction in BP. References 1. Worldwide prevalence of hypertension: a systematic review.
J Hypertens. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers.
J Occup Environ Med. Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, — Erdine S. How well is hypertension controlled in Europe? ESH Newsletter. Guidelines for the management of arterial hypertension, task force of the European Society of Hypertension and the European Society of Cardiology. J Hypertension. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. The heart outcomes prevention evaluation study investigators.
Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients.
Long term and short term changes in antihypertensive prescribing by office based physicians in the United States. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment HOT randomised trial. Measurement of blood pressure in adults. Am J Kidney Dis. Osterberg L, Blaschke T. Drug therapy: adherence to medication. Mar J, Rodriguez-Artalejo F.
Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension.
Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. Inadequate management of blood pressure in a hypertensive population.
Blood pressure reduction and cardiovascular prevention: an update including the — secondary prevention trials. Hypertens Res. LeLorier J. The value of lowering blood pressure. Can J Cardiol. Beneficial combinations of two or more antihypertensive agents. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients.
J Clin Hypertens. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro : evidence for voltage modulation of vascular dihydropyridine receptors. J Cardiovasc Pharmacol. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat.
Pathophysiology of salt-sensitive hypertension: a new scope of an old problem. Blood Purif. Available at: www. Plosker G, Robinson D. Wilkinson GR. Drug metabolism and variability among patients in drug response. Effects of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.
CAFE Investigators Differential impact of blood pressure lowering drugs on the central aortic pressure and clinical outcomes. Calcium antagonists — effects on cardiorenal risk in hypertensive patients. Kidney Int. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension Am J Hypertens 17 — A randomized controlled trial. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Nephrol Dial Transplant. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. Persistence, adherence, and risk discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med.
Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension.
Clin Exp Hypertens. Additive effect of valsartan on exercise tolerance in hypertensive patients treated with amlodipine J Hypertens 24 Suppl 6 Abstract PO4— [ Google Scholar ]. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in failure after single therapy EX-FAST study.
J Clin Hyperten Greenwich ; 10 — Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adults patients with stage 2 hypertension.
Clin Ther. Effects of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens.
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. Journal of the American Society of Hypertension. Abstract S Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
Adv Ther. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. Health economics in the Hypertension Optimal Treatment HOT study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
J Intern Med. Veterinary regulatory Overview Research and development Marketing authorisation Post-authorisation. Exforge RSS.
Table of contents Overview Authorisation details Product information Assessment history. Expand section Collapse section. The medicine can only be obtained with a prescription. Authorisation details. Product details Name Exforge. Publication details Marketing-authorisation holder Novartis Europharm Limited.
Product information. List item. You are therefore advised to be selective about which sections or pages you wish to print. Agents acting on the renin-angiotensin system. Treatment of essential hypertension. Assessment history. Changes since initial authorisation of medicine List item. Initial marketing-authorisation documents List item. European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive. European Medicines Agency recommendation on use of angiotensin-II-receptor antagonists during pregnancy.
More information on Exforge. Valsartan containing medicinal products: Article 31 referrals Renin-angiotensin-system RAS -acting agents: Article referral. Related content. Angiotensin-II-receptor antagonists sartans containing a tetrazole group: Article 31 referrals. Exforge: Paediatric investigation plan. But compliance may be a higher hurdle than efficacy. While a two-in-one pill is a significant advance in convenience, no combo can alter the fact that without telltale hypertensive aches and pains interrupting their lives, many patients tend to skip doses or worse, especially when side effects show up.
The compliance conundrum is something Novartis has been addressing across its blood-pressure portfolio. Patients on a Novartis' hypertension drug receive customized educational information each month. Novartis in November also designed 3-D graphics illustrating the havoc that uncontrolled high pressure can wreak on the body; dubbed "Dialogues," these visual aids are meant to help doctors drive home the point about why it's important for patients to adhere to therapy.
A Novartis-commissioned survey found, for instance, that while 85 percent of doctors believe they are fully explaining the risks of hypertension, only 50 percent of patients are taking their medications correctly.
Greenwood was conservative about Exforge's market potential. Iwicki disagreed with the projections.
0コメント